From today's Times:

Tiddler to watch

"ImmuPharma, steady at 46p, the biotech group which has a treatment of the disease Lupus in phase II trials, could benefit from the failure this week of trials of rival drug Rituxan. ImmuPharma's housebroker, Panmure Gordon, believes its client may attract the attention of Rituxan's developers, Genentech and Biogen Idec."

OK, I know we're all heartily sick of the promising small pharmacos, but I thought I'd bring this one to your attention because the demise of one much-hyped drug can indeed have a positive knock-on effect elsewhere. Furthermore, there doesn't seem to be much medication out there for Lupus.

This company is run by experienced people who have previously worked for some of the majors like GSK, Bristol-Myers Squibb, etc, and in investment banking. Their research results have been positive so far.

I made a good profit on these last year and the sp seems to have turned up again recently. Bought back again this morning. (NB: too small to trade in CFDs)

Full-year Prelims out today. Ciick on link:

Immupharma Full-Year Prelims

Glad I bought back in a few days ago - showing a good profit and I'm sure will have further to go.

Come and meet your CEO!

One2One Investor Presentation Invitation

Thursday 15th October

Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, W1J 5EB Starting at 6pm



One2One investor forum on Thursday 15th October, the directors of Lipoxen Plc (AIM: LPX), Plant Impact (AIM: PIM) and ImmuPharma PLC (AIM: IMM) will be presenting

The presentations will start at 6:00pm and finish at approx 7:30pm. Following the presentations will be a complimentary bar and an assortment of the finest seasonal hot & cold canap giving you the opportunity to speak with the directors and other investors. It is expected that this forum will be oversubscribed, so please register to avoid disappointment.


Register Here - http://www.sign-up.to/signup.php?fid=1865&pid=7163


If you have any problems registering or queries please email action@proactiveinvestors.com


These are superb events held in a wonderful setting in Mayfair, where private investors mingle with city professionals and network after the presentations.

The nearest tube statons are Green Park and Bond Street, which are five and seven minute walks away from the hotel respectively.



Lipoxen plc is a biopharmaceutical company focused on the development of new and improved biologic drugs and vaccines. Lipoxen has three proprietary patented technology platforms from which it has already progressed two products into clinical development. The first, SuliXen, is a long-acting insulin and the second, ErepoXen, is a long-acting erythropoietin (EPO). Lipoxen’s preclinical pipeline includes Factor XIII and vaccines against HIV, influenza and malaria. The Company has a low-risk business model and currently has commercial agreements with some of the world's leading biotechnology and pharmaceutical companies including Baxter, Schering-Plough, Sanofi-Aventis, the Serum Institute of India Limited, Genentech, Amgen and Genzyme.



Plant Impact specialises in plant stress relief. Plant Impact provide a dynamic and uncompromising new approach to crop nutrition and crop health, giving growers significantly increased marketable yields, more consistent quality with reduced environmental impact, leading to the ethically grown food demanded by consumers and the food chain.




ImmuPharma plc is a drug discovery and development company. The Company, along with its subsidiaries, is principally engaged in investing in pharmaceutical research and development companies. The Company has operations in Mulhouse, France and Basle, Switzerland. The ImmuPharma plc focuses to develop drugs to treat serious medical conditions. It has five drugs in development to treat: lupus, cancer, severe pain, highly resistant infections, such as methicillin-resistant staphylococcus aureus (MRSA) and inflammatory and allergic disorders. ImmuPharma was this week rated a ‘buy’ at Matrix with a 309p/share target price. ImmuPharma is currently trading at 85p

noble brokers target 220 p and could be 10 .read in one of articles in newspaper articles today forget where

They were magnificent results a couple of weeks ago and in a normal market I would have bought them when they dropped to the mid 80's which was ridiculous.

As you can gather I didn't as I didn't want my money tied up in a stock that wasn't moving.

Wish I had now! lol

Today's RNS:
ImmuPharma wins 'Best Technology 2009' Award at the AIM Awards

ImmuPharma PLC (LSE: IMM) the specialist discovery and development pharmaceutical company, has won the Best Technology Award at the AIM Awards 2009, organized by the London Stock Exchange.

The Award, announced at the AIM Awards Dinner in London on 15 October 2009, is presented to the company which reflects the innovation and entrepreneurial skills that are considered the cornerstone of the AIM culture.

Commenting on the award, Richard Warr, Chairman of ImmuPharma said: "ImmuPharma is honoured to receive the Best Technology Award at the 2009 AIM Awards Dinner. It is a prestigious award and I should like to thank the AIM community for recognising the innovation and entrepreneurial skills that have driven ImmuPharma forward over the last few years. This Award builds on our success at the European Mediscience Awards in June 2009 where ImmuPharma was awarded the Breakthrough of the Year Award. For ImmuPharma the journey is very much beginning and to have received such public recognition over the past year is particularly rewarding."

What a pleasant surprise to see today's rise - peaked at 140p but settled at 135p for now; up 10%. Could be something afoot.

This would explain yesterday's rise:

IMM - Positive results of Phase IIb trials

Hmm - back down it goes... Pity I wasn't around to keep an eye on this yesterday!

I don't often post, but this price drop doesn't make sense to me.

cont: The old adage of buy on rumour sell on news seems to have been over done here. Still, an opportunity to buy in again at sub 110p but I suspect we're going to trade sideways for some time once today's price settles.

Reckon you're right Lar... Probably be a while before we see a dramatic rise again but should be all right long term. They seem a well-run company with a good product

Well I doubled my holding during yesterday afternoon and broke one of my basic rules, i.e. never buy a falling share. So IMM is now more than 10% of my portfolio - another broken rule. Still, I feel less frustrated than yesterday . . . At least it didn't gap down first thing this morning as it did in July when the current charts have some similarities.

I reckon you were bowled a googly by the MM's Larboulois.

Was tempted to go in just before the close yesterday when it suddenly dipped to 105p but glad I resisted. Too many red herrings atm.

This really has got thumped today!

No it hasn't. Went down from 108p to about 106p.

More of a doosra than a googly Dealerdear.

As Ive already said, I dont normally post but Im early retired and sometimes I guess I let my heart rule my head. Now wheres this going youre wondering?

Allow me to tell you a little story. My wife has a very good friend whom she worked with for a long period of time. Weve lived in France for four years and Debbie her/our friend, frequently visits us. She separated from her partner about the same time as we came to France. Soon after this and following a number of tests she was diagnosed with lupus disease, an illness Id never heard of.

Im normally not sentimental about shares; Im a chartist and do lots of short term trades. I try to identify good points to enter and look for a quick 10 - 15% uplift and then Im out and looking elsewhere. Four years ago, I sold most of my shares save for some oil stocks when we came to live in France. I was very lucky because until this January, we didnt have a broadband connection in our village so most of my portfolio had been in cash for three years or so and I missed all the problems of last years slump. In June I restarted my subscriptions to real time prices etc. and started trading again. I came across ImmuPharma during September of this year, did some research not much I might add but I spotted that two directors had sold holdings of 10 million plus to M&G (so that was positive) and bought in three tranches (sorry French influence) in early October. This, after a fib retracement from the then September high, plus two other indicators I use which were about as good as they get. They rose very quickly to 120p mostly on two consecutive days mid month. But I then broke one of my rules and didnt sell; partly out of sentiment re Debbie and partly because I was up over 30% in less than a week, my best run ever on a supposedly short term trade. Over the next four weeks they tracked sideways and down 10% or so before breaking out above what I had as the 120.5p resistance line and seemingly off to new heights. On Wednesday of this week as they rocketed past 140p I began to doubt my carefully nurtured, regular trading system. I was now up 60% in little over 6 weeks. But this is where it went pear shaped because on Thursday morning after what I perceived to be an upbeat update on the Phase 11b trial , I bought in again, only to watch in astonishment as the rest of the day unfolded. Then as the price dropped below 110p, I made two more buys in the afternoon. This was a mistake within my own rules as noted by my own earlier posts about not buying falling shares and my thoughts that the share would now probably trade sideways. Under my rules, I dont buy shares that are falling or that I think will trade sideways. And therein lies the moral of the story. Stick to what youre good at and comfortable with and dont be greedy. And before somebody tells me Im well up with my trades - my frustration arises with me and not IMM. As I do my weekend resume, IMM now also holds another record in my current portfolio i.e. my biggest individual share price drop in a short period of time. And that is my frustration. Its not within my comfort zone. Logic dictates that I should sell all my holding on Monday morning, move elsewhere and wait for my indicators on IMM to come back together again. Sorry if Ive bored you good folk but Ive at least now Ive clarified my thoughts and got it off my chest. Now lets see if Prostrakan are worth another punt sometime this coming week.

Just read my last post - looks like something out of a Mills and Boon - not what this thread is about in some respects.

Yes - interesting novel Lar... But a really debilitating illness (I also know someone who suffers from it) and no 'pills' currently available.

According to The Times:
"ImmuPharma dropped 26p to 109p after the lupus specialist reported interim results for Lupuzor, its lead drug. The trial met its key target, but failed to meet statistical significance on one measurement."

Having re-read the RNS I still can't pinpoint the negative here, and wonder whether something may have come out at the conference call?

I don't think it could be anything too serious in the long-term, since all the primary endpoints were reached successfully, and were statistically significant.

From a pure trading point of view, it's a bore of course...

PSK yesterday joined IMM in 'keep clear territory' - my system of course.

Certainly wouldn't recommend buying just now. Took a profit yesterday, though should have done so earlier in the week... 85p is probably the level to watch out for and review before buying back in; could dip lower while we await further trial results next year.

Toya, I had 98p as a possible but weak support and it's being tested at the moment. My other indicators (that have served me well - here and elsewhere) suggest 88.5p as a 'worst case scenario' low, so I'm more or less with you at 85p. Not trying to score Brownie points here so it'll be interesting to see where IMM goes now.

As an aside and its just a comment, the Lloyds Rights Issue troubles me more than some. 13 billion plus theyre attempting to raise with shares issued at 37p against what was before the announcement a share price of circa 90p. (Now down to the mid 50p mark). I assume, in my simplistic way, that theyre trying to break the shackles of Government control. Holders have until the weekend to take up their rights. This one is going to be very interesting. As it was banks that started the financial mess, will share holders now see fit to shell out to support what I see as a questionable rights issue?

That apart, Im now 98% cash having seen my portfolio of 10 or so shares loose 18% this last month.

IMM down another 5% this morning. All in all, I think Ill be sitting tight for some time.

Oooh - got there much quicker than I ever expected but I wouldn't be a buyer just yet. Let's see if we now get a bounce . . . .

Yup, bounced alright but my 98p support is now likely to be a resistance. We'll see.

Despite a good day (especially if you bought in at sub 90p and sold at the 98p area), IMM needs to break 100p on the bid and hold (it's a sort of psychological barrier for chartists even though the share's been there before). Not saying it won't but if it opens up tomorrow I could be a buyer with a maximum three day horizon - still worried about the Lloyd's rights issue; in my humble opinion the Lloyd's Board are showing crass arrogance and gambling with the UK economy or am I on my own here?

With that in mind, not much else to say this side of next week.

Thanks for your comments Lar... haven't been checking in for a few days.

I think I'll stay on the sidelines for now - interesting to see that it has bounced today though

IMM kinda went up during Wednesday but I was never really convinced and up a tad more today. I'm only posting because my tried and tested indicators are all but at a 'buy'. (They've moved really quickly). Could be another good rise tomorrow which if it happened I would normally (well probably) buy in to but with my worries re Lloyds I'll wait till after the weekend; even if I miss out. Also keen to get back into JJB but they've been a bit iffy since the rights issue and are actually down 6%+ since I sold last week. I sold 10,000 Lloyds shares this morning at a big paper loss so now 100% cash but will take up my rights issue and hope they don't bomb before I can recover at least some of that loss.

IMM still not sure what to do and back below 100p and my indicators are still not quite right - they're meandering. I monitor about 50 shares; all smaller stocks - mostly AIM. In the last six months I've not seen such a high percentage of red on my screen as in the last few weeks. It's 90%+ this morning, IMM being one of the few that is blue - up 0.5p.

IMM looking much better. Still sticking under that 98p resistance but my indicators are almost right. About half of my ten or so 'favoured shares' that I'm monitoring are showing similar upturns. Much more blue than red these last few days and I've bought into GMG recently.

Bought 3000 yesterday and again today.

Got that wrong so out at 93p this afternoon.

Terrible market conditions so best left alone I feel

Now looks like it could drop to 78/80p support area.

Could have turned - nearly bought at 78p this morning but didn't. I'll see if it holds over the weekend.

I bought 10,000 last Thursday at 82p and another 2,500 this morning at 85.5p. I think we have a change of direction.

I thought about it at 81p a few days ago but the awful spread made me leave it alone.

Yup not good but I went for it.

Well, I sold all 12,500 (after 4 months) at 91p yesterday afternoon (up about 10% - no droolers please) and bought AVN which has made 5% already and has legs to go.

ImmuPharma's Lupuzor has blockbuster potential, reckons broker Cenkos
2:25 pm by Ian Lyall The broker is predicting peak sales potential of US$2 billion based on some fairly conservative assumptions Cenkos this morning initiated coverage of ImmuPharma (LON:IMM) with a ‘buy’ recommendation and 232 pence-a-share price target.

Navid Malik, the City broker’s respected head of life sciences, points out that ImmuPharma is in an enviable position for biotech in having a “phase-III ready asset”.

He was referring to Lupuzor, a potential treatment for the sometimes fatal auto-immune disease Lupus.

Taking it through the clinical stages of development to phase III means the group is in a position to maximise the value when it does finally find a partner willing to take on the further development of Lupuzor.

The US approval process should be far less treacherous than it might be for other drugs.

That’s because Food & Drug Administration has granted ImmuPharma approval to start the next phase of development with a Special Protocol Assessment.

This SPA is an important sign-off on the company’s clinical trial protocols.

The agency is essentially saying that, assuming no unforeseen issues, it will approve the drug if it matches or exceeds certain criteria.

Since this all happens before the data is generated, FDA tends to be conservative when handing out SPAs.

ImmuPharma has also received sign-off in Europe and Japan that will allow it move into the final clinical trial stage.

Cenkos said it has analysed Lupuzor and believes it has blockbuster potential.

This is primarily because it may eventually prove more efficacious than treatments currently on the market, such as the recently launched GlaxoSmithKline drug, Benlysta, and those currently making their way out onto the market.

The broker is predicting peak sales potential of US$2 billion based on some fairly conservative assumptions.

“We have analysed the Lupus market and believe that despite competitor products beginning Phase III trials, the mechanism of action for Lupuzor is unique and could position it as a blockbuster in the Lupus market,” said Malik.

In IPP-204106, the group also has a phase II cancer drug that has shown some “very promising survival data”, the analyst added.

“The data from preclinical studies is compelling, particularly in tumours that are difficult to treat, where the peptide demonstrated broad-spectrum anti-tumour activity,” he explained.

At 11.40am, the shares were changing hands for 54 pence (down 0.88 pence on the day), which is towards the bottom of its recent trading range.

The unveiling of a partner for Lupuzor would undoubtedly be a major catalyst for the stock.

Of course ImmuPharma previously had a deal for Cephalon that was worth as much as US$500 million in milestone and revenue payments.

However, the US biotech was forced to hand back the rights to the treatment following its takeover by Israeli group Teva.

Cenkos believes ImmuPharma could go down a similar route and find a new commercial partner willing to make a significant upfront payment, milestones and royalties to acquire the Lupuzor rights.

However there is an alternative.

“If it were to fund the product and complete the last phase of clinical trials using a contract research organisation, then instead of seeing a ‘teens’ based royalty on sales, we could see a much larger share of the potential upside – perhaps a revenue share model where net sales were split 50:50 and a contract sales force (specialist) was used to market the product,” Malik said.

“We already know that the bulk of sales in similar indications tend to come from specialist doctors and this often requires a much smaller and focused sales force – which means that there isn’t always a requirement for a large pharma sales team.”

Notification of Interim Results


http://www.moneyam.com/action/news/showArticle?id=4448448

Starting to recover, strong buying today. Up 8% today

12.5% rise today

up nearly 10%

:-))

Interim Results

INTERIM HIGHLIGHTS



· LupuzorTM, our candidate for the treatment of lupus which has been granted approval by the US Food and Drug Administration to begin Phase III trials under Special Protocol Assessment with Fast Track designation, continues to be the subject of licensing discussions with a number of possible partners



· IPP-204106, ImmuPharma's cancer programme, has begun dosing in a new clinical trial with the next generation of 'polyplexed Nucant'. This 'polyplexed Nucant' formulation has shown an impressive efficacy of about 10 times over the previous Nucant version in pre-clinical cancer models and represents a newly discovered form using the previous Nucant version together with a specific excipient that forms micro/nano structures (see separate announcement released today)



· IPP-204106, final results are available for the Phase I/IIa clinical trial where 6 out of the 14 patients had proven stabilisation with stabilisation lasting more than 6 months in 2 of the 6 patients. No serious drug related adverse events were reported



· Received the New Economy award for Best Medical Research and Development Company Europe 2012



· Strong cash position of £10.1 million



· Basic and diluted loss per share 2.17p and 2.17p respectively (30 June 2011: 2.59p and 2.59p).



http://www.moneyam.com/action/news/showArticle?id=4452077

RNS
RNS Number : 1519N
Immupharma PLC
26 September 2012



FOR IMMEDIATE RELEASE
26 September 2012




ImmuPharma plc



Cancer programme IPP-204106 progresses into further clinical trials



First cancer patients in new trial begin dosing



ImmuPharma plc (LSE:IMM) ("Immupharma" or the "Company" or the "Group"), the specialist drug discovery and development company, is pleased to announce that its cancer programme IPP-204106 has begun further clinical trials with the next generation of "polyplexed Nucant".



The first patients have started dosing in this new Phase I/II clinical trial.This "polyplexed Nucant" formulation has shown an impressive efficacy of about 10 times over the previous Nucant version in pre-clinical cancer models and represents a new discovery in that it combines the previous IPP-204106 Nucant version with a specific excipient that forms micro/nano structures. IPP-204106 has a novel mechanism of action aimed at preventing proliferation, inducing apoptosis and also controlling angiogenesis.



ImmuPharma has made promising progress with its anti-cancer nucleolin antagonist ("Nucant") peptide programme. Having received approval from the French regulatory authorities, Agence Francaise de Securite Sanitaire des Produits de Sante (AFSSAPS) it initiated an initial Phase I dose ranging tolerability and safety study in three hospitals in France which is now completed. Patients were suffering from different types of cancer including breast, lung and bladder cancers which had all metastasised. No serious drug related adverse events were reported. 6 out of the 14 patients had a proven stabilization and for 2 out of the 6 the stabilization lasted for more than 6 months.

For this next Phase I/II study based on the next generation "polyplexed Nucant", it is planned to re-evaluate the safety in a preliminary Phase I dose ranging tolerability study with the new formulation (first dose level about to be completed shortly) followed by a Phase II efficacy study designed to treat various cancers in approximately 30 patients to identify appropriate biomarkers. This trial will be conducted in three hospitals in Europe including the prestigious Institute Jules Bordet, an Integrated Multidisciplinary Centre which is the only autonomous hospital in Belgium totally dedicated to cancer. Our further intention is to conduct follow-up studies on patients showing the appropriate biomarkers with glioblastoma (brain tumour), metastatic melanoma, and pancreatic cancer where nucleolin plays a key role.

Recent scientific publications have demonstrated that by interfering with the pathway of nucleolin and other related membrane proteins, a strong growth inhibition of cancer cells as well as a strong induction of apoptosis was observed confirming initial results. In May 2011, IPP-204106 (also referred to as N6L) was chosen to feature on the front cover of 'Cancer Research', a prestigious medical journal of the American Association for Cancer Research. The article was entitled 'A Simple Approach to Cancer Therapy Afforded by Multivalent Pseudopeptides That Target Cell-Surface Nucleoproteins', and was authored by a number of researchers working at or with the CNRS, the research institution with which ImmuPharma is collaborating.



Dr Robert Zimmer, MD, PhD, ImmuPharma's President and Chief Scientific Officer, commented: "The clinical development of our cancer programme continues to be a key priority for ImmuPharma. It is therefore extremely encouraging to see the first patients dosed in this new trial. The improved formulation of the "polyplexed Nucant" is a great achievement for both ImmuPharma and our partner, the CNRS, and further strengthens our position in this field."

Good buying, keeping a close watch on this. Saw a sell rec yesterday due to late news

:-))

On wednesday - peel hunt said sell.

Immupharma (Berlin: 25I.BE - news) falls 4.8 percent as the drug discovery firm posts first-half results in which it says licensing discussions for its Lupus treatment, Lupuzor are continuing, leading Peel Hunt to repeat its "sell" rating on the stock.

ImmuPharma to present Lupuzor data later this month
8:15 am by Ian LyallImmuPharma is currently looking for a partner to take Lupuzor into the final phase of clinical trials.



ImmuPharma (LON:IMM) confirmed this morning that it will present data on its lead drug candidate Lupuzor to the prestigious annual American College of Rheumatology meeting later this month.

The ACR recently confirmed it had accepted the group’s abstract paper on phase IIb data from the Lupuzor trial.

The presentation will be given on November 14 by ImmuPharma’s chief scientific officer Robert Zimmer and Professor Daniel Wallace of the Cedars-Sinai Medical Centre in Los Angeles, a leading authority on Lupus.

Lupuzor was developed to treat the chronic autoimmune disease Lupus and has blockbuster potential.

It has also been given fast-track designation by America’s all-powerful Food & Drug Administration.

The company is currently looking for a partner to take Lupuzor into the final phase of clinical trials.

sp likely to go to sleep until the results of the lupuzor trials become imminent
given the likely high volatility, i have just sold the balance of my trading position at 130 for a modest profit, but shall retain the medium stake in my sipp

All looking good here imo
Can't believe how little posting goes on here. Have been in since 88p days so am happy with current performance. Will hold for the results of the trials..could be big gains to be made but all very speculative. dyor etc but GLA!

IMM
PI's excluded (shafted) yet again!

ImmuPharma raises £10m
Specialist drug discovery and development company ImmuPharma has raised £10m, gross, through a placing of 6,944,445 new ordinary shares at 144p apiece with new and existing investors


explains the weakness of sp over the last few days
that said, the placing was at 144 which is at only a very small discount

IMM has been clattered today by about 18% on the back of the following .....

Tim McCarthy, the Company's Non-executive Chairman (IMM), is currently on the board of Harvard Healthcare Limited ("Harvard"). On 5 March 2018 the Directors of Harvard passed a board resolution following which Harvard will be placed into a Creditors' Voluntary


however, i do not see the direct relevance to IMM
is there something i have missed?

160p to close the gap anybody?

Gap closed intra-day.

All looking good so far imvho. GLA

Lupuzor™ demonstrated a superior response rate over placebo* (52.5% vs 44.6% "responders"**) in the primary analysis on the Full Analysis Set of all 202 patients (including withdrawals who are considered non-responders). However, due to a high response rate in the placebo group, this superior response did not allow statistical significance to be reached (p = 0.2631) and the trial's primary end point was not met.

===============

OUCH!
serves me right but fortunately not too many
is there now anything left in this company top sell?
if they're lucky, they may be taken out by a bigger fish